Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: A prospective study

Annals of Hematology

Volumn 82, Issue 6, 2003, Pages 357-362

  Levin, M D ^a   de Veld, J C ^a   van der Holt, B ^a   van't Veer, M B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alloantibody; Leukodepletion; Platelet transfusion; Recovery

Indexed keywords

ALLOANTIBODY; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; HLA ANTIGEN; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOLOGY; LEUKOPENIA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SCREENING TEST; SPLENOMEGALY; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; ODDS RATIO; PLATELET COUNT; PLATELET TRANSFUSION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 0038150442     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0648-7     Document Type: Article

References (39)

1. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP (1997) Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 15:1143-1149
2. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G et al. (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 337:1870-1875
3. 9/l trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91:3601-3606
4. Safai-Kutti S, Zaroulis CG, Day NK, Good RA, Kutti J (1980) Platelet transfusion therapy and circulating immune complexes. Vox Sang 39:22-27
5. Kutti J, Zaroulis CG, Safai-Kutti S, Dinsmore RE, Day NK, Good RA (1981) Evidence that circulating immune complexes remove transfused platelets from the circulation. Am J Hematol 11:255-259
6. Hogge DE, Dutcher JP, Aisner J, Schiffer CA (1983) Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 14:363-369
7. Rosenfeld CS, Bodensteiner DC (1986) Detection of platelet alloantibodies by flowcytometry. Characterization and clinical significance. Am J Clin Pathol 85:207-212
8. Klingemann H-G, Self S, Banaji M, Deeg HJ, Doney K, Slichter SJ, Thomas ED, Storb R (1987) Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. Br J Haematol 66:115-121
9. Bishop JF, McGrath K, Wolf MM, Mathews JP, Luise De T, Holdsworth R, Yuen K, Veale M, Whiteside MG, Cooper IA, Szer J (1988) Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 71:383-387
10. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW (1990) Transfusion of ABO mismatched platelets leads to early platelet refractoriness. Br J Haematol 75:408-413
11. Bishop JF, Matthews JP, Mcgrath K, Yuen K, Wolf MM, Szer J (1991) Factors influencing 20-hour increments after platelet transfusions. Transfusion 31:392-396
12. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N (1993) The role of ABO matching in platelet transfusion. Eur J Haematol 50:110-117
13. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH (1994) Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66:200-205
14. Novotny VMJ, Doorn van R, Witvliet MD, Claas FHJ, Brand A (1995) Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 85:1736-1741
15. Alcorta I, Pereira A, Ordinas A (1996) Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol 93:220-224
16. Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, Riggert J, Schleyer E, Kern W, Hiddemann W, Koehler M (1997) Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 74:185-189
17. Novotny VMJ (1999) Prevention and management of platelet transfusion refractoriness. Vox Sang 76:1-13
18. Fabris F, Soini B, Sartori R, Randi ML, Luzzatto G, Girolami A (2000) Clinical and laboratory factors that affect the posttransfusion platelet increment. Transfus Sci 23:63-68
19. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH (2001) Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538
20. Hussein MA, Lee EJ, Schiffer CA (1990) Platelet transfusions administered to patients with splenomegaly. Transfusion 30:508-510
21. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y (1998) Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation-a prospective analysis. Transfusion 38:839-847
22. Eernisse JG, Brand A (1981) Prevention of platelet refractoriness due to HLA antibodies by administration of leucocytepoor blood components. Exp Haematol 9:77-83
23. Murphy MF, Metcalf P, Thomas H, Eve J, Ord J, Lister TA, Waters AH (1986) Use of leucocyte-poor blood components and HLA-matched platelet donors to prevent HLA alloimmunization. Br J Haematol 62:529-534
24. Brand A, Claas FHJ, Voogt PJ, Wasser MNJM, Eernisse JG (1988) Alloimmunization after leucocyte-depleted multiple random donor platelet transfusions. Vox Sang 54:160-166
25. Marwijk van-Kooy M, Prooyen van HC, Moes M, Bosma-Sants I, Akkerman JWN (1991) Use of leucocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 77:201-206
26. Daly PA, Schiffer CA, Aisner J, Wiernik PH (1980) Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 243:435-438
27. Velden van der KJ, Sintnicolaas K, Löwenberg B (1986) The value of a 51Cr platelet lysis assay as crossmatch test in patients with leukaemia on platelet transfusion therapy. Br J Haematol 62:635-640
28. Lee EJ, Schiffer CA (1987) Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 70:1727-1729
29. Brubaker DB, Romine M (1987) Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy. Am J Hematol 26:341-352
30. Freedman J, Garvey MB, Salomon de Friedberg Z, Hornstein A, Blanchette V (1988) Random donor platelet crossmatching: comparison of four platelet antibody detection methods. Am J Hematol 28:1-7
31. Kickler T, Kennedy SD, Braine HG (1990) Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 30:622-625
32. Godeau B, Fromont P, Seror T, Duedari N, Bierling P (1992) Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients. Br J Haematol 81:395-400
33. Kurz M, Greinix H, Höcker P, Kahls P, Knoebl P, Mayr WR, Pober M, Panzer S (1996) Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 95:564-569
34. Sanz C, Freire C, Alcorta I, Ordinas A, Pereira A (2001) Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 41:762-765
35. Slichter SJ (1997) The trial to reduce alloimmunization to platelets study group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337:1861-1869
36. Davis KB, Slichter SJ, Corash L (1999) Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 39:586-592
37. Levin M-D, Veld de JC, Holt van der B, Veer van 't MB (2003) Screening for allo antibodies in the serum of patients receiving platelet transfusions: a comparison of the ELISA, lymphocytotoxicity and the indirect immunofluorescence technique. Transfusion 43:72-77
38. Sintnicolaas K, Vries de W, Linden van der R, Gratama JW, Bolhuis RLH (1991) Simultaneous flow cytometric detection of antibodies against platelets, granulocytes and lymphocytes. J Immunol Methods 142:215-222
39. Gratama JW, Linden van der R, Vries de W, Veld de J, Levin M-D, Sintnicolaas K, Veer van't MB, Bolhuis RLH (1998) Simultaneous detection of IgM and IgG antibodies against platelets, lymphocytes, and granulocytes by flow cytometry. Infus Ther Transf Med 25:317-324